A5018875411- Cancer Genomics and Diagnostics
- Bioinformatics and Genomic Networks
- Computational Drug Discovery Methods
- Cutaneous Melanoma Detection and Management
- Single-cell and spatial transcriptomics
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- COVID-19 and healthcare impacts
- Cardiac tumors and thrombi
- Gene expression and cancer classification
- Telemedicine and Telehealth Implementation
- Vascular Tumors and Angiosarcomas
- Economic and Financial Impacts of Cancer
- Cutaneous lymphoproliferative disorders research
- RNA regulation and disease
- Health Systems, Economic Evaluations, Quality of Life
- Nonmelanoma Skin Cancer Studies
- Skin Protection and Aging
- Sarcoma Diagnosis and Treatment
- Hair Growth and Disorders
- melanin and skin pigmentation
- Mathematical Biology Tumor Growth
- Sex and Gender in Healthcare
- Cancer Research and Treatments
The University of Texas Southwestern Medical Center
2023-2024
Texas Christian University
2021-2024
University of Cambridge
2023-2024
Cancer Research UK Cambridge Center
2023
University of North Texas
2021
University of North Texas Health Science Center
2021
University of Southern California
2018
Molecular analysis of circulating and disseminated tumor cells (CTCs/DTCs) has great potential as a means for continuous evaluation prognosis treatment efficacy in near-real time through minimally invasive liquid biopsies. To realize this potential, however, methods molecular these rare must be developed validated. Here, we describe the integration imaging mass cytometry (IMC) using metal-labeled antibodies implemented on Fluidigm Hyperion Imaging System into workflow previously established...
<p>Supplementary Figures 1-20</p>
<div>Abstract<p>The intertumor and intratumor heterogeneity of triple-negative breast cancers, which is reflected in diverse drug responses, interplays with tumor evolution. In this study, we developed a preclinical experimental analytical framework using patient-derived xenografts (PDTX) from patients treatment-naïve cancers to test their predictive value personalized cancer treatment approaches. Patients matched PDTXs exhibited concordant responses neoadjuvant therapy two trial...
<p>Short-term olaparib treatment does not cause major genomic changes. <b>A,</b> Growth curves displaying raw data of model 1006 treated with for 11 weeks (purple) or untreated controls (black). Dotted line indicates end treatment, after which, tumors were left to progress until size limits. <b>B,</b> Correlation plots comparing mean VAFs mutations between and (left) post-treated (right) samples. <i>R</i> value calculated using the Spearman...
<p><i>In vivo</i> treatment causes permanent changes to a tumor’s drug response profile. <b>A,</b> Experimental framework of <i>in and <i>ex profiling. <b>B,</b> High-throughput screening data dissociated PDTX cells. AUC plots display the each tumor drugs tested vivo</i>. Color indicates which was previously exposed. <b>C,</b> Dose–response curves models 1040 (top) 1141 (bottom) olaparib BMN-673. Plots compare untreated...
<p>Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends</p>
<p>Olaparib treatment causes permanent phenotypic changes due to TF reprogramming. <b>A,</b> Heatmap displaying <i>z</i>-score (scaled by row) of the top 250 strong and variable genes. Clustering analysis performed using Euclidean distances. Columns indicate PDTX samples (labeled mouse number). <b>B,</b> Top 10 significant gene sets normalized enrichment score (NES) between untreated post-treated samples, identified GSEA (Hallmark sets). DN, down....
<p>A preclinical platform of TNBC PDTXs. <b>A,</b> Clinical treatment and responses the patient cohort from which PDTX models used in this study were derived. <b>B,</b> Experimental framework coclinical trial. <b>C,</b> Top, correlation plots comparing GSEA enrichment scores (Hallmark C6 gene sets) for 1006, 1040, 1022, 1141. Bottom, mutation VAFs model 1006. Correlation was calculated between passages, sister mice, multiple regions same tumor using...
<p>A coclinical trial framework reveals concordant patient–PDTX drug responses. <b>A,</b> Experimental (consisting of two designs) and associated analytical approach, with modeling metrics used to assess response. <b>B</b> <b>C,</b> TV growth curves displaying linear mixed model fits designs 1 (<b>B</b>) 2 (<b>C</b>) over treatment duration. Treatment arm for each PDTX corresponds the clinical matched patient....
<p>PDTXs identify patient-specific drug responses and model patient- treatment-specific regrowth dynamics. <b>A,</b> Experimental framework to test alternative treatments <b>B</b> <b>C,</b> Mean difference in daily growth rate between the treated untreated groups during treatment (<b>B</b>) after has ceased (<b>C</b>). <b>D</b> <b>E</b>, TV curves displaying linear mixed fits of PDTX models 1040 (left)...
Importance Melanoma in Black individuals has an annual incidence of approximately 1 100 000 people. Most studies melanoma patients have used population databases, which lack important, precise clinical details. Objective To identify patient-level and tumor-level characteristics patients. Design, Setting, Participants This case series included with at 2 tertiary care centers (University Texas Southwestern [UTSW] Medical Center Parkland Health), affiliated a single institution, UTSW Dallas,...
Sarcomas constitute approximately 1% of adult cancers and 8%–10% paediatric cancers. Undifferentiated pleomorphic sarcoma (UPS) is a type soft-tissue (STS) characterised by dedifferentiated cancer cells. The most common sites metastasis for UPS include the lungs, liver, bones regional lymph nodes. Brain rare, affecting only 1%–8% STS patients. This report presents unique case woman in her 80s with TET2 -mutant metastatic to lung brain.
The inter- and intra-tumor heterogeneity of triple negative breast cancers (TNBC), which is reflected in diverse drug responses, interplays with tumor evolution. Here, we developed a preclinical experimental analytical framework using treatment-naive TNBC patient-derived xenografts (PDTX) to test their predictive value personalized cancer treatment approaches. Patients matched PDTX exhibited concordant responses neoadjuvant therapy two trial designs dosing schedules. This platform enabled...
Abstract Imaging mass cytometry (IMC) is a novel technology with the potential of multiplex proteomic profiling rare circulating and disseminated tumor cells (CTCs DTCs) immune from liquid biopsies. The high-definition single-cell analysis (HD-SCA) identifies CTCs DTCs by virtue morphometric fluorescent staining exact locations all cells, which could be further characterized using downstream genomics proteomics platform. This study aims to develop employ metal-labeled antibody panels for...
The disruption caused by the COVID-19 pandemic has disproportionately affected cancer patients' access to care. As a result, many specialists in United States, including oncologists, have adopted telemedicine-a transition largely made possible reforms insurer reimbursement schemes. Years after crisis, there will continue be steady demand for remote outpatient visits, particularly oncology. However, health system heavily influenced reimbursements, strategies optimize oncology care not...
ABSTRACT Triple negative breast cancers (TNBC) exhibit inter- and intra-tumour heterogeneity, which is reflected in diverse drug responses interplays with tumour evolution. Here, we use TNBC patient-derived xenografts (PDTX) as a platform for co-clinical trials to test their predictive value explore the molecular features of response resistance. Patients matched PDTX exhibited mirrored neoadjuvant therapy clinical trial. In parallel, additional clinically-relevant treatments were tested...